According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
A number of other brokerages also recently commented on ZIOP. HC Wainwright restated a buy rating and issued a $5.50 target price on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. Laidlaw started coverage on shares of ZIOPHARM Oncology in a research note on Monday, April 1st. They issued a buy rating and a $7.50 target price on the stock. BidaskClub upgraded shares of ZIOPHARM Oncology from a hold rating to a buy rating in a research note on Thursday, March 14th. Finally, Lake Street Capital started coverage on shares of ZIOPHARM Oncology in a research report on Thursday, April 4th. They issued a buy rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. ZIOPHARM Oncology has an average rating of Buy and an average target price of $5.75.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. On average, equities analysts forecast that ZIOPHARM Oncology will post -0.3 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Ibex Investors LLC purchased a new stake in shares of ZIOPHARM Oncology in the 4th quarter worth approximately $755,000. MSD Partners L.P. lifted its position in shares of ZIOPHARM Oncology by 222.1% in the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock worth $20,544,000 after purchasing an additional 7,575,758 shares during the period. BlackRock Inc. lifted its position in shares of ZIOPHARM Oncology by 1.3% in the 3rd quarter. BlackRock Inc. now owns 9,289,620 shares of the biotechnology company’s stock worth $29,727,000 after purchasing an additional 121,880 shares during the period. Vanguard Group Inc. lifted its position in shares of ZIOPHARM Oncology by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 8,783,696 shares of the biotechnology company’s stock worth $28,108,000 after purchasing an additional 194,441 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of ZIOPHARM Oncology by 21.5% in the 4th quarter. Private Advisor Group LLC now owns 141,132 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 24,966 shares during the period. 35.20% of the stock is owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
See Also: Stock Symbol
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.